Get started

Financials · XENE

Xenon Pharmaceuticals Inc. (XENE) financials

For the twelve months ended Sep 30, 2026, Xenon Pharmaceuticals Inc. reported $0 of revenue and -$428.73M of net income.

Revenue, TTM
$0
Revenue growth, YoY
-100.0%
Net income, TTM
-$428.73M
Free cash flow, TTM
-$357.11M
EPS, diluted, TTM
-$4.70
Cash
$82.56M
Market cap
$3.92B
Annual revenue$7.50M
FY2016FY2025
Annual net income-$345.91M
FY2016FY2025
Annual free cash flow-$279.92M
FY2016FY2025

XENE revenue and earnings growth

XENE revenueQ3 2026$0

5Y CAGR
-25.3%
10Y CAGR
-7.0%

XENE revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $7.50M, compared with $0 in fiscal 2024. Compound annual growth was -25.3% over 5 years and -7.0% over 10 years.

XENE net incomeQ3 2026-$110.44M

XENE net income was -$110.44M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$90.90M a year earlier. For the full fiscal 2025 it was -$345.91M, compared with -$234.33M in fiscal 2024.

XENE EPSQ3 2026-$1.11

XENE diluted EPS was -$1.11 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.15 a year earlier. For the full fiscal 2025 it was -$4.36, compared with -$3.01 in fiscal 2024.

XENE free cash flowQ3 2026-$90.61M

XENE free cash flow was -$90.61M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$72.03M a year earlier. For the full fiscal 2025 it was -$279.92M, compared with -$184.46M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$7.50M$0$0$9.43M$18.44M$32.17M$6.83M-$311.0K$1.80M
Research and development$300.94M$210.39M$167.51M$105.77M$75.46M$50.52M$38.84M$23.63M$25.57M$19.83M
Selling, general and admin$79.63M$68.90M$46.54M$32.81M$21.97M$12.94M$10.80M$8.41M$7.31M$6.79M
Operating income-$373.07M-$279.30M-$214.05M-$129.14M-$78.99M-$31.30M-$42.82M-$38.04M-$32.58M-$24.82M
Interest expense-----$484.0K$1.43M$1.39M--
Pre-tax income-$344.89M-$238.42M-$182.69M-$125.25M-$78.89M-$29.09M-$41.62M-$34.52M--
Income tax$1.02M-$4.09M-$292.0K$118.0K-$6.0K-$257.0K-$23.0K-$24.0K--
Net income-$345.91M-$234.33M-$182.39M-$125.37M-$78.88M-$28.84M-$41.59M-$34.50M-$30.70M-$23.00M
EPS, basic-$4.36-$3.01-$2.73-$2.06-$1.77-$0.81-$1.54-$1.63-$1.71-$1.48
EPS, diluted-$4.36-$3.01-$2.73-$2.06-$1.77-$0.81-$1.54-$1.63-$1.72-$1.48
Diluted shares79.3M77.9M66.9M60.5M43.6M34.5M25.9M19.4M18.0M15.5M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$199.16M$142.71M$148.64M$57.24M$175.69M$45.01M$24.75M$67.75M$20.49M$17.09M
Short-term investments$349.72M$484.19M$489.44M$534.85M$376.09M$131.99M$116.60M$51.55M$23.18M$47.05M
Receivables-$1.47M$874.0K$986.0K$2.77M$1.82M$813.0K$151.0K$438.0K$200.0K
Current assets$560.65M$635.26M$644.96M$600.30M$559.02M$181.78M$144.87M$121.33M$44.82M$65.67M
Total assets$633.16M$798.14M$964.80M$754.15M$572.01M$189.19M$147.70M$122.43M$46.12M$67.49M
Current liabilities$41.79M$35.59M$27.27M$22.70M$14.32M$14.78M$43.38M$4.12M$4.08M$3.59M
Short-term debt------$4.65M-$700.0K-
Long-term debt------$10.89M$15.01M$6.10M-
Total debt------$15.54M$15.01M$6.80M-
Total liabilities$51.40M$43.24M$36.88M$32.65M$21.97M$17.83M$55.72M$19.13M$10.19M$3.59M
Shareholders' equity$581.76M$754.90M$927.92M$721.50M$550.03M$171.35M$91.98M$103.30M$35.93M$63.90M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$279.12M-$181.39M-$151.11M-$101.03M-$69.50M-$48.12M-$4.71M-$34.72M-$28.73M-$19.57M
Capital expenditures$799.0K$3.08M$5.62M$2.89M$2.05M$2.64M$1.24M$507.0K$315.0K$279.0K
Free cash flow-$279.92M-$184.46M-$156.73M-$103.92M-$71.55M-$50.76M-$5.95M-$35.23M-$29.04M-$19.85M
Investing cash flow$218.00M$165.00M-$111.39M-$293.40M-$246.77M-$16.82M-$66.21M-$28.99M$24.29M-$47.84M
Financing cash flow$117.11M$12.13M$353.52M$278.47M$447.54M$85.80M$27.52M$111.59M$7.07M$23.96M
Stock-based compensation$53.71M$50.72M$32.37M$20.38M$10.02M$5.68M$2.92M$2.63M$2.24M$2.16M
Depreciation and amortization$2.54M$2.56M$2.06M$1.41M$906.0K$644.0K$429.0K$586.0K$649.0K$864.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY---100.0%-48.8%-42.7%371.0%---82.8%-88.4%
Operating margin-4974.3%---1368.9%-428.4%-97.3%-627.0%--10474.3%-1376.4%
Net margin-4612.1%---1328.9%-427.8%-89.7%-609.1%--9872.7%-1275.5%
Free cash flow margin-3732.2%---1101.6%-388.1%-157.8%-87.2%--9337.9%-1100.7%
Return on equity-59.5%-31.0%-19.7%-17.4%-14.3%-16.8%-45.2%-33.4%-85.4%-36.0%
Return on assets-54.6%-29.4%-18.9%-16.6%-13.8%-15.2%-28.2%-28.2%-66.6%-34.1%
Current ratio13.4217.8523.6526.4439.0312.303.3429.4610.9818.31
Debt to equity------0.170.150.19-

Source: XBRL data Xenon Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

XENE peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
XENE$0-100.0%-$428.73M-$3.92B
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

XENE FAQ

7 questions
  • What is XENE revenue?
    Xenon Pharmaceuticals Inc. (XENE) reported $0 of revenue for the twelve months ended Sep 30, 2026. That is down 100.0% from the year before. Revenue for fiscal 2025 was $7.50M.
  • Is XENE profitable?
    No. Xenon Pharmaceuticals Inc. reported a net loss of $428.73M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does XENE have?
    Xenon Pharmaceuticals Inc. reported $82.56M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • What is XENE free cash flow?
    Xenon Pharmaceuticals Inc. generated -$357.11M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$356.10M less capital expenditures.
  • What is XENE earnings per share?
    Diluted earnings per share were -$4.70 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did XENE last report financial results?
    The latest statements here come from Xenon Pharmaceuticals Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.
  • Where does this XENE financial data come from?
    Quantisnow builds these statements from the structured XBRL data Xenon Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.